The selective S1P1 modulator ameliorates murine Sclerodermatous Chronic Graft Versus Host Disease
Project/Area Number |
16K19713
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Dermatology
|
Research Institution | Kanazawa University |
Principal Investigator |
KANO MIYU 金沢大学, 附属病院, 医員 (60756237)
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | S1P1受容体阻害剤 / 全身性強皮症 / 慢性cGVHD / 慢性GVHD |
Outline of Final Research Achievements |
Sphingosine-1-phosphate (S1P) / S1P receptor signal regulates the differentiation and migration of immunocompetent cells and is an important therapeutic target in systemic sclerosis. A novel selective S1P1 receptor inhibitor was administered to chronic GVHD model mice. Skin and pulmonary fibrosis was improved and inflammatory cell infiltration into the skin was decreased.By contrast, S1P1 receptor inhibitor increased the frequency of regulatory T cells in the spleen of Scl-cGVHD mice.In addition, S1P1 receptor inhibitor attenuated the mRNA expression of extracellular matrix and fibrogenic cytokines such as IL-1β and IL-6, in the skin of Scl-cGVHD mice.These results suggested that the selective S1P1 inhivitor is a promising candidate for treating patients with SSc and Scl-cGVHD.
|
Report
(3 results)
Research Products
(1 results)